Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588229328> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2588229328 endingPage "vi138" @default.
- W2588229328 startingPage "vi138" @default.
- W2588229328 abstract "SNX-5422 is an orally bioavailable pro-drug of SNX-2112, a highly potent and selective heat shock protein 90 (Hsp90) inhibitor. In preclinical studies, the effects of SNX-2112 and EVR appear at least additive. Previously, at doses of 42-100 mg/m2 of SNX-5422 taken every other day (qod), 2 of 3 patients (pts) with refractory NETs achieved stable disease for >8 cycles. EVR, a mammalian target of rapamycin (mTOR) inhibitor, now has FDA approval for pancreatic NETs and nonfunctional gastrointestinal and pulmonary NETs. Eligible pts had unresectable gastro-entero-pancreatic or pulmonary NETs and <5 prior lines of anti-cancer treatment. Each cycle (C) was 28 days: SNX-5422 was dosed qod each morning for 21/28 days, starting at 50 mg/m2 with standard 3 + 3 dose escalation, and EVR was dosed 10 mg once daily in the evening for 28 days, with dose de-escalation allowed based on EVR toxicity. The primary objective was to determine the maximum tolerated dose (MTD) of SNX-5422 when given with EVR. Secondary objectives included safety and efficacy. We enrolled 17 pts (10 male, 7 female; median age 59 years) with NETs. The MTD of SNX-5422 was determined to be 75 mg/m2 in combination with EVR. Dose limiting toxicity was 1 case of G3 diarrhea. Other adverse events in ≥2 pts possibly related to either or both agents included anemia, anorexia, blurred vision (3 pts, all mild, all continued SNX-5422), diarrhea, fatigue, hyponatremia, mucositis, nausea, increased creatinine (EVR), dehydration (EVR), maculopapular rash (EVR), thrombocytopenia (EVR), and weight loss (EVR). All events were G1/G2, except for G3 diarrhea (1 SNX, 1 EVR, 1 both), increased creatinine (1, EVR), hyponatremia (2, EVR). There was also 1 pt who developed possibly related G4 hyponatremia with combination therapy. Six pts with NETs are continuing therapy at this time. Of 14 NET pts evaluable for efficacy, 2 had partial responses (14%; both ongoing, 1 >25 cycles), 8 stable disease (57%), and 4 (29%) progressive disease as best response. Of 8 pts with stable disease, 2 ongoing (1 >23 cycles), 3 study withdrawal (1 personal reasons [minor response], 2 for tolerability) and 3 progressed. The addition of SNX-5422 75 mg/m2 to EVR in pts with advanced NETs warrants further study." @default.
- W2588229328 created "2017-02-24" @default.
- W2588229328 creator A5001185639 @default.
- W2588229328 creator A5009327463 @default.
- W2588229328 creator A5022063365 @default.
- W2588229328 creator A5022339242 @default.
- W2588229328 creator A5039064680 @default.
- W2588229328 creator A5043871151 @default.
- W2588229328 creator A5064404426 @default.
- W2588229328 creator A5081606866 @default.
- W2588229328 creator A5082283453 @default.
- W2588229328 creator A5083000419 @default.
- W2588229328 creator A5090608376 @default.
- W2588229328 date "2016-10-01" @default.
- W2588229328 modified "2023-10-16" @default.
- W2588229328 title "Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)" @default.
- W2588229328 doi "https://doi.org/10.1093/annonc/mdw369.08" @default.
- W2588229328 hasPublicationYear "2016" @default.
- W2588229328 type Work @default.
- W2588229328 sameAs 2588229328 @default.
- W2588229328 citedByCount "3" @default.
- W2588229328 countsByYear W25882293282021 @default.
- W2588229328 countsByYear W25882293282022 @default.
- W2588229328 countsByYear W25882293282023 @default.
- W2588229328 crossrefType "journal-article" @default.
- W2588229328 hasAuthorship W2588229328A5001185639 @default.
- W2588229328 hasAuthorship W2588229328A5009327463 @default.
- W2588229328 hasAuthorship W2588229328A5022063365 @default.
- W2588229328 hasAuthorship W2588229328A5022339242 @default.
- W2588229328 hasAuthorship W2588229328A5039064680 @default.
- W2588229328 hasAuthorship W2588229328A5043871151 @default.
- W2588229328 hasAuthorship W2588229328A5064404426 @default.
- W2588229328 hasAuthorship W2588229328A5081606866 @default.
- W2588229328 hasAuthorship W2588229328A5082283453 @default.
- W2588229328 hasAuthorship W2588229328A5083000419 @default.
- W2588229328 hasAuthorship W2588229328A5090608376 @default.
- W2588229328 hasBestOaLocation W25882293281 @default.
- W2588229328 hasConcept C126322002 @default.
- W2588229328 hasConcept C2778496288 @default.
- W2588229328 hasConcept C2779802037 @default.
- W2588229328 hasConcept C2780580376 @default.
- W2588229328 hasConcept C29730261 @default.
- W2588229328 hasConcept C71924100 @default.
- W2588229328 hasConceptScore W2588229328C126322002 @default.
- W2588229328 hasConceptScore W2588229328C2778496288 @default.
- W2588229328 hasConceptScore W2588229328C2779802037 @default.
- W2588229328 hasConceptScore W2588229328C2780580376 @default.
- W2588229328 hasConceptScore W2588229328C29730261 @default.
- W2588229328 hasConceptScore W2588229328C71924100 @default.
- W2588229328 hasLocation W25882293281 @default.
- W2588229328 hasOpenAccess W2588229328 @default.
- W2588229328 hasPrimaryLocation W25882293281 @default.
- W2588229328 hasRelatedWork W1980701009 @default.
- W2588229328 hasRelatedWork W2034795531 @default.
- W2588229328 hasRelatedWork W2051732006 @default.
- W2588229328 hasRelatedWork W2083653180 @default.
- W2588229328 hasRelatedWork W2092093742 @default.
- W2588229328 hasRelatedWork W2465463735 @default.
- W2588229328 hasRelatedWork W2468258954 @default.
- W2588229328 hasRelatedWork W4249502477 @default.
- W2588229328 hasRelatedWork W4253034792 @default.
- W2588229328 hasRelatedWork W7096573 @default.
- W2588229328 hasVolume "27" @default.
- W2588229328 isParatext "false" @default.
- W2588229328 isRetracted "false" @default.
- W2588229328 magId "2588229328" @default.
- W2588229328 workType "article" @default.